
Hanwen Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/229662/publications.pdf Version: 2024-02-01



HANWEN WANC

#	Article	IF	CITATIONS
1	Systems biology of angiogenesis signaling: Computational models and omics. WIREs Mechanisms of Disease, 2022, 14, e1550.	3.3	19
2	Dynamics of tumor-associated macrophages in a quantitative systems pharmacology model of immunotherapy in triple-negative breast cancer. IScience, 2022, 25, 104702.	4.1	15
3	Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer. , 2021, 9, e002100.		29
4	Integrating single cell sequencing with a spatial quantitative systems pharmacology model spQSP for personalized prediction of triple-negative breast cancer immunotherapy response. ImmunoInformatics, 2021, 1-2, 100002.	2.2	18
5	QSPâ€Ю: A Quantitative Systems Pharmacology Toolbox for Mechanistic Multiscale Modeling for Immunoâ€Oncology Applications. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 484-497.	2.5	34
6	Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model. , 2020, 8, e001141.		31
7	A Quantitative Systems Pharmacology Model of T Cell Engager Applied to Solid Tumor. AAPS Journal, 2020, 22, 85.	4.4	26
8	Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors. Frontiers in Bioengineering and Biotechnology, 2020, 8, 141.	4.1	35
9	Simulations of Combination Therapy in Hepatocellular Carcinoma Using a Quantitative Systems Pharmacology Model. FASEB Journal, 2020, 34, 1-1.	0.5	0
10	<i>In silico</i> simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model. Royal Society Open Science, 2019, 6, 190366.	2.4	54